Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in

Thrombosis is the major common endpoint in most human diseases. In the coronary circulation, occlusive thrombi and/or the rupture of atherosclerotic plaque causes myocardial infarction, and in the cerebral circulation thrombosis, causes ischemic stroke. In the venous circulation, venous thromboembolism (VTE), manifesting clinically as pulmonary embolus and deep vein thrombosis (DVT), is a frequent complication among inpatients, and contributes to longer hospital stays with increased morbidity and mortality.1 Until perhaps 5 years ago, heparinoids (unfractionated heparin, low molecular weight heparin [LMWH], and fondaparinux) and vitamin K antagonists (VKAs: warfarin, acenocoumarol, phenprocoumarol) were the only options for the prevention of thrombotic stroke in atrial fibrillation, and of VTE in general.2 Although effective, these traditional drugs have several practical, management, and clinical disadvantages, a fact that our colleagues in industry have not been slow to recognize and address by developing improved drugs, now collectively known as nonvitamin K antagonist oral anti coagulants (NOACs)2–4 (Table 1). These agents are steadily replacing the heparinoids and VKAs in both inpatient and outpatient prevention and treatment of thrombosis. Figure 1 illustrates the point of action of these drugs on the coagulation pathway.

The first NOAC to be used in the clinic, dabigatran (a direct anti thrombin), was followed by three others that target coagulation Factor Xa (FXa): rivaroxaban, apixaban, and edoxaban.5–8 All have, or are expected to have, licenses for the treatment and/or prevention of VTE and stroke in a number of well-defined different clinical situations, such as in acute DVT or pulmonary embolus, after orthopedic surgery, and in atrial fibrillation. However, more NOACs are set to join the group,9 but many ask why do we need so many? The answer lies in consideration of the different pharmacokinetics and pharmacodynamics of each of the NOACs, and how these relate to the frequent comorbidities and other aspects of the patients. Although all of the current NOACs are preferable to the traditional drugs, each still has niggling problems that can be overcome with improved agents. Important factors influencing the choice of one particular NOAC over another include patient preference, once or twice daily dosing, drug–drug interactions, renal clearance, and hepatic metabolism. The latter is relevant as these drugs can influence and be influenced by the various cytochrome 450 enzymes and by the permeability glycoprotein (P-gp) pump. Furthermore, as the first NOACs to be trialed (ximelagratan) brought fears of long-term liver damage, all subsequent NOACs are now required to be assessed in this respect. Fortunately, all other NOACs have
An additional problem is of renal failure because of high degree of renal excretion of the four licensed NOACs; they cannot be used when the creatinine clearance/estimated glomerular filtration rate is very low, as this effectively means that the half-life of the NOAC is extended, leading to the increased risk of hemorrhage. Newcomers to this busy market, which include darexaban and betrixaban, both FXa inhibitors, must address these issues.

The new kids on the block

Preclinical studies of darexaban found it to be rapidly absorbed with or without a meal, with both blood and plasma concentrations peaking approximately 45 minutes after dosing, and with 51.9% excreted via feces and 46.4% via urine. It appears to have minimal interactions with digoxin and rifampicin, implying that the potential for drug–drug interactions between darexaban and CYP3A4 or P-gp-inducing agents is low. Although full-scale clinical development of this drug was stopped in 2011, darexaban has been trialed in the prevention

Table 1 Disadvantages of traditional anticoagulants and NOAC reflection

<table>
<thead>
<tr>
<th>Traditional agents</th>
<th>NOAC reflection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin K antagonists</td>
<td>Routine blood test unnecessary</td>
</tr>
<tr>
<td>Regular blood tests (perhaps 4-weekly, hence expensive and inconvenient to manage)</td>
<td>Wider therapeutic window</td>
</tr>
<tr>
<td>Narrow therapeutic window</td>
<td>Fewer such interactions</td>
</tr>
<tr>
<td>Interactions with many other drugs and lifestyle choices</td>
<td>No effect on the embryo</td>
</tr>
<tr>
<td>Teratogenic to the embryo</td>
<td>Short half-life</td>
</tr>
<tr>
<td>Long half-life (hence insensitive to need for a rapid change)</td>
<td></td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>Oral</td>
</tr>
<tr>
<td>Needs to be injected</td>
<td>Predictable pharmacokinetic and pharmacodynamics, so routine blood test unnecessary</td>
</tr>
<tr>
<td>Unreliable pharmacokinetic and pharmacodynamics, hence need for active monitoring with APTT</td>
<td>No major interaction with the platelet</td>
</tr>
<tr>
<td>Small risk of heparin-induced thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td>Low molecular weight heparin</td>
<td>Oral</td>
</tr>
<tr>
<td>Needs to be injected</td>
<td>No major interaction with the platelet</td>
</tr>
<tr>
<td>Very small risk of heparin-induced thrombocytopenia</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: NOAC, nonvitamin K antagonist oral anticoagulant; APTT, activated partial thromboplastin time.

Initiator and propagation stages
eg Factor V, Factor VII, Factor VIII

Generation of Factor Xa from Factor X

Warfarin

Prothrombin

Thrombin

Fibrinogen

Fibrin

Factor Xa inhibitors eg Rivaroxaban, Apixaban, Edoxaban, Darexaban, Betrixaban, LMWH

Direct thrombin inhibitors eg Dabigatran

Indirect thrombin inhibitors (acting via antithrombin) eg unfractionated heparin LMWHs, fondaparinux

Notes: On the right-hand side, the indirect parenteral anticoagulants, unfractionated heparin and low molecular weight heparin (LMWH), act by effectively inhibiting thrombin and Factor Xa, respectively. Dabigatran acts directly on thrombin, while rivaroxaban, apixaban, edoxaban, darexaban and betrixaban act directly on Factor Xa. The effect of warfarin (left-hand side) is to reduce levels of certain coagulation factors, the building blocks of the fibrin clot, so an effective thrombus is slow to form (if at all). Small arrows – enzymatic reactions. Large arrows – action of inhibitors.
of VTE after abdominal and orthopedic surgery.\textsuperscript{17–19} It has also been trialed in acute coronary syndromes,\textsuperscript{20} as has rixaroxaban (with successful end point outcomes),\textsuperscript{21} although guidelines from the European Society of Cardiology Working Group on Thrombosis recommends the use of newer antiplatelet agents over addition of NOACs in this setting.\textsuperscript{22} Thus, although there is a modest amount of promising literature on this drug, any advantage it can bring over its competitors remains to be seen and, should clinical development restart, robust additional data will be sought.

Betrixaban is further along the path to widespread acceptance, as fully described by the review from Chan et al in the current issue of the journal.\textsuperscript{23} This drug is important for several reasons. First, it has less than 1\% metabolism via cytochrome P450, compared with 57\%, <32\%, and <25\% for the other anti-FXa NOACs and <2\% in the case of dabigatran. This means it is likely to have far fewer drug interactions and is more likely to be safe in those with liver disease. Second, renal excretion is in the region of 6\%–13\%, compared to >80\%, 66\%, 25\%, and 35\% for the other NOACs. The implication of this is that it is likely to be safe in those with severe renal failure, a feature unique to this drug, and so a highly sought-after characteristic. However, the fact that it has a slightly longer half-life (20 hours) compared to its competitors (9–15 hours) has both advantages (eg, less of a clinical issue if a dose is missed) and disadvantages (eg, longer time to wash out if hemorrhage). Betrixaban has been successfully trialed in the prevention of VTE in acutely ill medical patients, following orthopedic surgery and in stroke prevention in atrial fibrillation.

**When things go wrong**

A problem with all drugs is of overdose, and in the case of anticoagulants, this is hemorrhage. The short half-life of the NOACs (like that of heparins) means that simply stopping the drug should lead to a resumption of normal hemostasis. Nevertheless, antidotes have been called for and are in development.\textsuperscript{24} An antidote for dabigatran, idarucizumab (the antigen-binding site of a monoclonal antibody) is well into clinical development,\textsuperscript{25,26} as is a modified recombinant FXa (andexanet alpha), which lacks enzymatic activity, and which may inhibit all of the anti-FXa NOACs.\textsuperscript{27} Other antidotes in development include ciraparantag, a synthetic small molecule that reverses dabigatran, apixaban, and rivaroxaban, as well as subcutaneous fondaparinux and LMWH in vivo. Until such time as these become available (as possible afterward), severe hemorrhage is treated with blood components.\textsuperscript{28–32}

A strength of the NOACs is that because their pharmacokinetics and pharmacodynamics are stable, routine blood monitoring is not required. However, there are several instances (as in overdose, or before emergency surgery) where the assessment of the actual anticoagulant status of the individual is needed. Regrettably, the most widely used laboratory tests, the prothrombin time and activated partial thromboplastin time, are unsuitable for the NOACs.\textsuperscript{32–36} Nevertheless, it is likely that the effectiveness of darraxaban (should it ever be needed) and of betrixaban can be determined, as with the other FXa inhibitors, by an anti-FXa assay such as the HepTest.

**Conclusion**

The NOACs are becoming an increasingly popular option for the most common causes and treatment of venous thrombosis and of thrombotic stroke in atrial fibrillation. The problem of renal excretion, and so, inadvisability in the face of low creatinine clearance, may be addressed by betrixaban, little of which is excreted via this organ. The problems of antidotes for these drugs are being addressed, and they may become available in 2016.

**Disclosure**

Dr Blann declares hospitality, speaker fees, and research funds from Pfizer, Bayer, Daiichi-Sankyo and Boehringer-Ingelheim. The University of Birmingham Centre for Cardiovascular Sciences at City Hospital, Birmingham, recruits into anticoagulant trials. The author reports no conflicts of interest in this work.

**References**


